cyclopentane has been researched along with Parkinsonian Disorders in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (76.47) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amalric, M; Brotchie, JM; Johnston, TH; Lopez, S; Neuville, P; Schann, S; Turle-Lorenzo, N | 1 |
| BOOIJ, J | 1 |
| DUNHAM, WF; EDWARDS, CH | 1 |
| KOWALEWSKI, K; MAHAUX, J | 1 |
| Alam, M; Danysz, W; Dekundy, A; Schmidt, WJ | 1 |
| Amalric, M; Jouve, L; Kerkerian-Legoff, L; Lopez, S; Salin, P; Turle-Lorenzo, N | 1 |
| BEHREND, RC | 1 |
| SANYAL, RK | 1 |
| LEIGH, D; SCHWAB, RS | 2 |
| DIERCKS, AL | 1 |
| PAKESCH, EF | 1 |
| JORDAN, J; UIBERALL, E | 1 |
| WINTHER, K | 1 |
| Konieczny, J; Kuter, K; Ossowska, K; Pilc, A; Wardas, J | 1 |
| COBB, CT; LEIGH, D; SCHWAB, RS | 1 |
| SCHWAB, RS; TILLMANN, WR | 1 |
17 other study(ies) available for cyclopentane and Parkinsonian Disorders
| Article | Year |
|---|---|
Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Catalepsy; Cyclopentanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Haloperidol; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Wistar; Reaction Time; Receptors, Adenosine A2; Receptors, Metabotropic Glutamate; Tricarboxylic Acids; Xanthines | 2008 |
The treatment of Parkinson's syndrome with parpanite.
Topics: Cyclopentanes; Parkinsonian Disorders | 1948 |
Parkinsonism treated with parpanit.
Topics: Cyclopentanes; Parkinsonian Disorders | 1948 |
Study of the influence of the ethylaminoethyl ester of phenyl-cyclopentane-carboxylic acid (parpanit) on the elevation of the combustion of parkinson patients.
Topics: Cyclopentanes; Parkinsonian Disorders | 1948 |
Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Basal Ganglia; Behavior, Animal; Catalepsy; Cyclopentanes; Disease Models, Animal; Dopamine; Excitatory Amino Acid Antagonists; Hypokinesia; Idazoxan; Male; Motor Activity; Muscle Rigidity; Neuroprotective Agents; Neurotoxicity Syndromes; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Adrenergic, alpha-2; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Rotenone; Serotonin; Substantia Nigra; Time Factors | 2009 |
Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity.
Topics: Animals; Cyclopentanes; Disease Models, Animal; Excitatory Amino Acid Agonists; Male; Neural Pathways; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Stereoisomerism; Substantia Nigra; Subthalamic Nucleus; Tricarboxylic Acids | 2012 |
[Parpanit therapy of extrapyramidal disorders].
Topics: Basal Ganglia Diseases; Cyclopentanes; Parkinsonian Disorders | 1951 |
A case of Parkinson's disease treated with parpanit.
Topics: Cyclopentanes; Parkinson Disease; Parkinsonian Disorders | 1949 |
[Parpanit in the treatment of Parkinson disease (transl)].
Topics: Cyclopentanes; Parkinson Disease; Parkinsonian Disorders | 1949 |
[Experience with therapeutic use of parpanit].
Topics: Cyclopentanes; Parkinsonian Disorders | 1950 |
[Treatment of extrapyramidal motor disturbances].
Topics: Cyclopentanes; Movement; Paralysis; Parkinsonian Disorders | 1950 |
[Modern drugs in the treatment of parkinsonism and similar diseases].
Topics: Cyclopentanes; Mephenesin; Paralysis; Parkinsonian Disorders; Phenothiazines | 1950 |
[Treatment of paralysis agitans with some new preparations: parpanit, diparcol, and phenergan].
Topics: Cyclopentanes; Histamine; Parkinson Disease; Parkinsonian Disorders; Phenothiazines; Promethazine | 1950 |
The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
Topics: Animals; Corpus Striatum; Cyclopentanes; Dopamine Antagonists; Dose-Response Relationship, Drug; Enkephalins; Excitatory Amino Acid Agonists; Gene Expression Regulation; Glutamic Acid; Haloperidol; Male; Neural Pathways; Opioid Peptides; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; RNA, Messenger; Substantia Nigra; Synaptic Transmission; Tricarboxylic Acids; Up-Regulation | 2007 |
Parpanit in the treatment of Parkinson's disease.
Topics: Cyclopentanes; Humans; Parkinson Disease; Parkinsonian Disorders | 1949 |
Treatment of Parkinson's disease with parpanit; a preliminary report.
Topics: Cyclopentanes; Humans; Parkinson Disease; Parkinsonian Disorders | 1948 |
Artane in the treatment of Parkinson's disease; a report of its effectiveness alone and in combination with benadryl and parpanit.
Topics: Cyclopentanes; Diphenhydramine; Parkinson Disease; Parkinsonian Disorders; Trihexyphenidyl | 1949 |